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Abstract Nowadays, an increasing number of minimal
invasive treatment alternatives to hysterectomy may be
offered to the patient. In determining the appropriate
treatment option, the patient has a distinct dilemma if a
minimal invasive treatment with lesser effect than hyster-
ectomy should be chosen or if a hysterectomy should be
chosen which is a major surgery and requires longer
recovery than the minimal invasive alternative. Quality-of-
life (QoL) questionnaires that take subjective health
perception into account are currently used to assess the
treatment effects. The objective of this literature study is to
determine and discuss the role of QoL as an outcome in
randomized controlled trials (RCT) or systematic reviews
of RCTs that study the treatment effect of hysterectomy
compared to that of minimal invasive alternatives. A
systematic literature search was performed in the PubMed
database and in the Cochrane database to find randomized
trials and systematic reviews of randomized trials, compar-
ing hysterectomy with minimal invasive or conservative
treatment options with sufficient follow-up using satisfac-
tion, health status, and quality of life as outcomes. The
results were based on nine randomized trials and two
systematic reviews. The differences are mostly in favor of
hysterectomy. In two out of four studied treatment
alternatives, the satisfaction or health status is different in
favor of hysterectomy while the QoL is equivalent. After
2 years of follow-up, differences between both groups have
disappeared, possibly because of the crossover effect.
Possible reasons for the lesser response of QoL compared
to satisfaction or health status are discussed. The funda-
mental question if patients have a better quality of life at all
times if they choose for a minimal invasive alternative of
hysterectomy remains unresolved. Information, individual-
ization, and freedom of choice before surgery probably best
serve the sense of well being and quality of life thereafter.
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Background
Despite an increasing number of alternative minimal
invasive treatment options, the hysterectomy in the
Netherlands is still frequently performed in premenopaus-
al patients with uterine symptoms. According to a Dutch
hospital-based database (Prismant), approximately 16,000
hysterectomies are performed each year. Alternative
treatment options are medical treatment, including the
levonorgestrel-delivering intrauterine system (LNG-IUS),
endometrial ablation, embolization or occlusion of uterine
vessels, and the partial removal of uterine structures such
as polyps, fibroids, and the uterine corpus (subtotal
hysterectomy).
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The dilemma for patients and doctors in the choice
between hysterectomy and minimal invasive or conserva-
tive treatment is the tradeoff between a faster recovery in
minimal invasive surgery and the possibly lesser effect of
the treatment.
There have been different ways in evaluating treatment,
such as satisfaction and health status (e.g., symptom score).
In 1952, WHO reformulated the definition of health being
“not only the absence of disease or infirmity, but also the
presence of physical, mental and social wellbeing,” hereby
introducing a subjective element in the definition of health
[1]. The—subjective—perception of health determines the
quality of life (QoL). Instead of using outcomes such as
satisfaction of treatment or health status, the treatment
effect is increasingly measured as QoL. QoL is measured
ideally by questionnaires that have been validated to be
reliable, reproducible, and specific [2]. In generic QoL
questionnaires, the general health is inquired, while in disease-
specific QoL, the questions apply more to specific medical
situations. The latter questionnaires are more appropriate to
assess treatment effects. QoL should be distinguished from
health status (e.g., menstrual score) or satisfaction after
treatment, which are considered causal items where the QoL
is based upon. Although QoL seems an appropriate outcome
to compare conventional and minimal invasive treatment, the
results sometimes differ from the health status or the level of
satisfaction. It is therefore a matter of debate on what results
patients should be counseled.
The objective of this literature study is to determine and
discuss the role of QoL as an outcome in randomized
controlled trials (RCT) or systematic reviews of RCTs that
study the treatment effect of hysterectomy compared to that
of minimal invasive alternatives.
Method
A systematic literature search was performed in the
PubMed database and in the Cochrane database to find
systematic reviews of randomized trials, comparing hyster-
ectomy with minimal invasive or conservative treatment
options [medical treatment including LNG-IUS, endome-
trial ablation, and uterine artery embolization (UAE) or
ligation] with sufficient follow-up using satisfaction, health
status, and quality of life as outcomes. If no systematic
reviews or later published data were available, then
randomized trials were also included. The search terms
(“menorrhagia” [Mesh] OR “leiomyoma” [Mesh] AND
“Quality of Life” [Mesh] AND “Hysterectomy” [Mesh])
limited to randomized trials or reviews were used in the
PubMed database as well as in the Cochrane database.
From the PubMed database, 26 articles meeting the
search terms were found, of which two were Cochrane
systematic reviews [3, 4]. There were four randomized
trials detected that met the criteria [5–8]. Two articles on
first-generation endometrial ablation [9, 10] met the criteria
but were appropriately reported in the identified systematic
review. Checking cross references from this review, four
more randomized trials were identified [11–14]. From the
Cochrane database using the Mesh terms “hysterectomy”
and “Quality of life,” two hits with regard to systematic
reviews were retrieved and 43 trials. The two systematic
reviews were already found in the PubMed database. Three
more potentially suitable trials were found but were excluded
[15–17]. In one study that compared uterine artery ligation
with hysterectomy, only the design was described [17].
Follow-up lacked in another study [15], and quality of life
was not used as an outcome in the third excluded study
[16]. With the mesh term “uterine artery embolization,” one
more Cochrane review was detected [18]. However, this
review addressed short-term results, and no follow-up was
reported, while later published articles reported follow-up
data on uterine artery embolization [6, 7]. The process of
selection was done by two authors (JH, HB) independently.
No cases of disagreement occurred.
On four minimal invasive or conservative therapies, we
found systematic reviews or RCTs comparing them with
hysterectomy. These alternative treatment options were
hormonal medication [4, 5], LNG-IUS (Mirena) [4, 8],
first-generation endometrial ablation [3, 10], and UAE [6,
7]. On the other minimal invasive treatment options
(myomectomy, occlusion of the uterine artery), no random-
ized trials could be found in the aforementioned databases
and the international trial register (http://clinicaltrials.gov/
ct2/search/browse?brwse=cond_cat_BXS).
Findings
The randomized trials on which the reviews were based on
are presented in Table 1. Conclusions of these reviews and
articles are briefly reported below according to satisfaction,
health status, and quality of life.
Medical treatment
In the Cochrane review of Marjoribanks et al. [4], studies
were systematically collected that compared medical
treatment with surgery, including hysterectomy in premen-
opausal women with heavy menstrual bleeding. Eight
studies met the inclusion criteria. The authors randomized
a total of 821 women, 411 receiving surgery and 410
receiving medical treatment.
The authors conclude in the abstract: “surgery, especially
hysterectomy, reduces menstrual bleeding at one year more
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than medical treatments but LNG-IUS appears equally
effective in improving quality of life. The evidence for
longer term comparisons is weak and inconsistent. Oral
medication suits a minority of women long term.”
We will address the comparison of hysterectomy and
LNG-IUS separately in the next section.
In one study, hysterectomy was the intervention which
was compared with oral medical treatment [5], and
validated quality-of-life questionnaires were used. In this
study of Kuppermann et al. [5], 63 premenopausal patients
with abnormal uterine bleeding and dissatisfied with
medical treatments, including medroxyprogesterone, were
randomized to continuation of that medical treatment or
hysterectomy. The outcomes were two summary indexes of
the short form (SF)-36. The primary outcome was the
mental component score; secondary outcomes were the
physical component score, symptom relief, and satisfaction.
In an intention-to-treat analysis, only a weak difference of
the mental component score of the SF-36 between the
groups was demonstrated after 6 months, while the
difference in satisfaction was more pronounced in favor of
hysterectomy (Table 2). After 2 years, no differences
between groups were found in the SF-36 and satisfaction.
At that time, 33/63 (53%) of patients of the medical
treatment arm had “crossed over” to hysterectomy.
LNG-IUS
The part of the systematic review of Marjoribanks [4]
addressing hysterectomy versus LNG-IUS was based on the
randomized trial of Hurskainen et al. [8, 19]. In this trial,
107 patients with heavy menstrual bleeding were treated
with hysterectomy and 118 with the LNG-IUS. Two articles
after 1 and 5 years reported the health-related quality of life
(HRQL) to be equal between both treatment arms based on
an intention-to-treat analysis (Table 3). After 5 years of
follow-up, general health status as measured by visual
analog scale was significantly improved in the hysterecto-
my group (p=0.04), but not in the LNG-IUS group (p=
0.08), with no substantial difference between groups.
Satisfaction was assessed by a five-level question and did
not differ between treatment arms. These data are not
shown in the results section, but only mentioned in the
abstract. Therefore, it is not possible to assess the level of
satisfaction in both groups. After 5 years, a hysterectomy
was performed in 42% of the LNG-IUS patients. In this
Table 1 Randomized controlled trials comparing conservative or minimal invasive surgery with hysterectomy
Author Year Number of
patients
Control treatment QoL questionnaire Health status
instrument
Follow-up
Kupperman [5] 2004 63 Oral medical SF-36 Satisfaction 6 months, 2 years, 5 years
Hurskainen [8, 15] 2001, 2004 236 LNG-IUS SF-36, EQ5 Satisfaction 1 year, 5 years
Crosignani [9] 1997 85 TCRE a SF-36 Satisfaction 2 years
Dwyer [12] 1993 196 TCRE SF-36 Satisfaction 2, 8 years
Gannon [13] 1991 51 TCRE – Satisfaction 1 year
O'Connor [14] 1997 172 TCRE General health Satisfaction 2 years
Pinion [11] 1994 202 TCRE Psychosocial adjustment
to illness
Satisfaction 4 years
Hehenkamp [6] 2008 177 Uterine artery
embolization
SF-36, EQ5 Satisfaction 2 years
Edwards 2007 51 Uterine artery
embolization
SF 36 Symptom
score
1 year
TCRE transcervical resection of the endometrium
Table 2 Differences between treatment arms in mental component score of the SF-36 and the physical component score of the SF-36
Difference between medical treatment and hysterectomy arm (+ in favor of hysterectomy)
SF-36 Follow-up 6months p Follow-up 2years p
Mental component summary +6 (CI 0.4–12) 0.04 +3 (CI −2–7) 0.25
Physical component summary +3 (CI −2–8) 0.21 −2 (−5–1) 0.19
Symptom resolution (%) 46 (29–63) <0.001 14 (−2–31) 0.9
Satisfaction with symptom level 37 (21–52) <0.001 6 (−7–20) 0.36
Randomized between continuation of medication and hysterectomy were 236 premenopausal patients with abnormal uterine bleeding [5]
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subgroup, the HRQL was significantly lower than in the
group who had the LNG-IUS after 5 years in situ.
In the conclusion, the authors state that “the LNG-IUS
may improve HRQL at relatively low cost, undoubtedly
enhances patient choice, and may reduce surgery-related
costs.”
First-generation ablation
In the Cochrane review of Lethaby et al. [3], five RCTs of
endometrial destruction versus hysterectomy with a total of
752 participants met the criteria and were included. Patients
were analyzed according to the intention-to-treat analysis,
and a significant difference of the satisfaction rate was
found in favor of the hysterectomy after 1 and 2 years. See
Table 4. After 3 and 4 years, the differences lost its
statistical significance.
Although many quality-of-life scales reported no differ-
ences between surgery groups, there was some evidence of
a greater improvement in general health for hysterectomy
patients after 1 and 2 years, when compared to those who
had endometrial destruction. This was also the case after
2 years of follow-up in the SF-36 domains social
functioning and pain. After 4 years, this difference between
groups had narrowed and was just outside the 0.05 level of
significance.
Reintervention rate in patients treated by ablation ranged
from 14% after 1 year to 38% (only hysterectomies) after
4 years.
The authors conclude that “endometrial destruction is an
alternative to hysterectomy that should be offered to
women with heavy menstrual bleeding. There are high
satisfaction rates, shorter operation time and hospital stay,
earlier recovery and reduced post-operative complications.”
They stress however that the patient should be informed
about the higher risk of reoperation after endometrial
destruction.
Uterine artery embolization
In two randomized trials, the UAE is compared to
hysterectomy in terms of satisfaction and quality of life.
In the EMMY trial [6], more than 90% of patients in both
groups were at least moderately satisfied after a follow-up
of two years, but a larger proportion of the patients in the
hysterectomy group was satisfied to very satisfied (45/75=
60%) compared with the UAE group (34/81=42%; p=
0.026). However, the primary outcome, the quality of life
measured by generic (SF36 and EQ5) as well as health-
related questionnaires, did not differ after 2 years. The
“crossover” to hysterectomy in the UAE group was 25%. In
the conclusion of the abstract, it is stated that “on the basis
of HRQOL results, the authors determined that UAE is a
good alternative to hysterectomy.” In the second study of
Edwards et al. [7], patients undergoing UAE (n=106) were
compared to patients undergoing surgery (43 hysterecto-
mies and eight myomectomies). After 1 year of follow-up,
no differences of the eight components of the SF-36 scores
were found between both groups, while the symptom scores
were better in the surgical group (p=0.03). In the UAE
group, 21 patients (20%) required within 1 year a
reintervention, such as hysterectomy or repeated emboliza-
tion for inadequate symptom control. The authors conclude
in the abstract that “In women with symptomatic fibroids,
the faster recovery after embolization must be weighed
against the need for further treatment in a minority of
patients.”
Discussion
While in the past the hysterectomy was the treatment of
choice in case of benign gynecological disorders, nowa-
days, many alternative treatment options are available that
are less invasive and preserve the uterus. In the office, the
challenge is to support patients in their dilemma of
choosing hysterectomy with adequate symptom relief or
minimal invasive treatment with a risk of lesser symptom
control.
In this systematic literature review, articles are addressed
that study in a randomized way the comparison of hysterec-
tomy and a conservative or lesser invasive alternative, such as
EQ5 dimensions Difference in EQ5 score Confidence interval
Follow-up 1 year 0.0 −0.05–0.05
Follow-up 5 years 0.02 −0.05–0.009
Table 3 Treatment effect
(difference between groups) in
EQ5 score in 232 patients after
LNG-IUS and hysterectomy
after 1 and 5 years
Table 4 Treatment effect with regard to satisfaction rate and quality
of life comparing endometrial ablation and hysterectomy in a
systematic review
Patient satisfaction N studies N patients Effect size (95%CI)
1 year 3 529 0.46 (0.24–0.88)
2 years 3 354 0.31 (0.16–0.59)
3 years 1 82 0.32 (0.08–1.37)
4 years 1 148 0.52 (0.21–1.26)
Statistics with Pete odds ratio [3]
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medical treatment, endometrial ablation, and uterine artery
embolization. In general, the differences in satisfaction of
treatment or in health status between treatment arms are more
prominent in terms of statistical significance than the differ-
ences of QoL. The difference is mostly in favor of
hysterectomy which is presented in Table 5. In two out of
four studied treatment alternatives, the satisfaction or health
status is different in favor of hysterectomy while the QoL is
equivalent in both treatment arms. After 2 years of follow-
up, differences between both groups have disappeared,
possibly because of the crossover effect.
How can it be explained that this response of treatment
satisfaction is better than the response of QoL and what
consequence may it have for our recommendations to the
patient? Two suppositions may explain that quality of life is
less or not at all responsive after treatment. First, we can
assume that there is a difference in quality of life which is not
detected. The second explanation is that, despite differences
in symptom control between treatment arms, the patients
experience indeed no differences in quality of life.
Let us first elaborate on the possibility that there is a
difference in quality of life between hysterectomy and the
minimal invasive alternative which is not detected. In all
studies that report a difference in QoL that is not statistically
significant, this difference is in favor of the hysterectomy.
Therefore, insufficient power may play a role, although in
other studies with comparable numbers comparing gyneco-
logical surgery, significant treatment effects have been
demonstrated by QoL questionnaires (SF-36) [20].
In all trials, generic QoL questionnaires were used, such
as the SF-36, the Euroqol five (EQ5) dimensions, and the
Nottingham health profile. It is well established that
disease-specific questionnaires are more responsive to
treatment effects than generic questionnaires that are
designed to measure health-related quality of life across a
wide variety of diseases [21]. Nowadays, validated instru-
ments are available that measure QoL in benign gyneco-
logical disease, such as the uterine fibroid symptom list
designed by Spies et al. [22]. Also, for menorrhagia,
various lists are reported in the literature [23]. It is
recommended for optimal sensitivity and responsiveness
in clinical trials to use a combination of a generic and a
disease-specific questionnaire [24].
The second possibility is that there is no difference in
QoL between groups indeed despite a significantly differing
symptom control between treatment arms. This could be
explained by the fact that patients undergoing a minimal
invasive treatment take a lesser effect into account.
Consequently, they are not unhappy in all cases if the
treatment has failed. It is well known from preference trials
that the majority of women are willing to accept a failure
rate of the minimal invasive option up to 50% in escaping a
hysterectomy [25].
In the reported studies, a large proportion of patients
randomized to the minimal invasive alternative treatment
eventually “crossed over” to hysterectomy (25–53%).
Intention-to-treat analysis may equalize effects and explain
the disappearance of the differences over time. This
accounts for quality of life and to a lesser extent for health
status (satisfaction) as the difference in health status is
larger from the start. In the study of Hehenkamp et al. [6],
after 2 years of follow-up, satisfaction differed significantly
between treatment arms (UAE and hysterectomy) while no
time effect and treatment effect of the quality of life were
reported.
Conclusion
In conclusion, the fundamental question if patients have a
better quality of life at all times if they choose for a
minimal invasive alternative of hysterectomy remains
Table 5 Semiquantitative ranking based on statistical significance of treatment effect (difference between treatment arms) in terms of symptom
relief (satisfaction) and quality of life (++, +, ±, −)
Difference between treatment arms in favor of hysterectomy
Treatment compared with hysterectomy Relief of symptoms (satisfaction) Quality of life Crossover to hysterectomy (%)
++, +, ±, − p value or CI ++, +, ±, − p value
Medical treatment [5]a ++ <0.001 + 0.04 53
LNG-IUS (Mirena) [8]b − Not stated − 0.60 42
Endometrial ablation (1st generation) [9]c + Significant ± NS 38
Uterine artery embolization [6]d + 0.04 − 0.62 25
a After 6 months of follow-up. QoL SF-36 mental component score, satisfaction symptom list of SF-36 physical component score
bWith the Euroqol 5 after 2 years of follow-up. Satisfaction was only mentioned in the abstract.
c After 2 years of follow-up, the Euroqol 5 showed no difference between groups; however, general health perception in the SF-36 did
d After 2 years of follow-up. The p value is of the Euroqol 5 QoL questionnaire. No other QoL instruments showed a significant difference between groups.
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unresolved. Some do and some do not. As quality of life
depends on the extent to which patients’ expectations are
matched by reality [26], adequate information beforehand
on the surgical options, tailored to the particular situation of
the patient, is of utmost importance. In this way, the
individual preference of the patient can be best explored. If
the patient is well prepared on certain risk of treatment
failure, the eventual period of complaints and concerns to
come to a decision of an often more invasive reintervention
is better coped with and may not be reflected in the QoL.
The QoL of patients crossing over has been reported
significantly worse than in the group of patients that
comply with their original treatment [8].
Information, individualization, and freedom of choice
before surgery probably best serve the sense of well being
and quality of life thereafter.
Open Access This article is distributed under the terms of the
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